422000 Kenpaullone - CAS 142273-20-9 - Calbiochem

422000
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Empirical FormulaCAS #
      C₁₆H₁₁BrN₂O 142273-20-9

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      422000-1MG
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service
          Contact Customer Service

          Plastic ampoule 1 mg
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA potent, cell-permeable, and reversible inhibitor of glycogen synthase kinase-3β (IC50 = 230 nM), Lck (IC50 = 470 nM), and cyclin-dependent kinases (Cdks). Inhibits Cdk1/cyclin B (IC50 = 400 nM), Cdk2/cyclin A (IC50 = 680 nM), Cdk2/cyclin E (IC50 = 7.5 µM), and Cdk5/p25 (IC50 = 850 nM). Also inhibits other kinases such as c-Src (IC50 = 15 µM), casein kinase II (IC50 = 20 µM), ERK1 (IC50 = 20 µM), and ERK2 (IC50 = 9 µM). Inhibition is competitive with respect to ATP binding.
          Catalogue Number422000
          Brand Family Calbiochem®
          Synonyms9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one, NSC-664704
          References
          ReferencesBain, J., et al. 2003. Biochem. J. 371, 199.
          Buolamwini, J.K. 2000. Curr. Pharm. Des. 6, 379.
          Schultz, C., et al. 1999. J. Med. Chem. 42, 2909.
          Zaharevitz, D.W., et al. 1999. Cancer Res. 59, 2566.
          Product Information
          CAS number142273-20-9
          ATP CompetitiveY
          FormYellow-brown solid
          Hill FormulaC₁₆H₁₁BrN₂O
          Chemical formulaC₁₆H₁₁BrN₂O
          ReversibleY
          Structure formula ImageStructure formula Image
          Applications
          Biological Information
          Primary TargetGsk-3β
          Primary Target IC<sub>50</sub>230 nM, 470 nM, 400 nM, 680 nM, 7.5 µM, 850 nM, 15 µM, 20 µM, 20 µM, 9 µM against glycogen synthase kinase-3β, Lck IC50, Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, and Cdk5/p25, c-Src, casein kinase II, ERK1, and ERK2
          Purity≥95% by HPLC
          Physicochemical Information
          Cell permeableY
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Standard Handling
          Storage -20°C
          Protect from Light Protect from light
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Packaging Information
          Packaged under inert gas Packaged under inert gas
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          422000

          References

          Reference overview
          Bain, J., et al. 2003. Biochem. J. 371, 199.
          Buolamwini, J.K. 2000. Curr. Pharm. Des. 6, 379.
          Schultz, C., et al. 1999. J. Med. Chem. 42, 2909.
          Zaharevitz, D.W., et al. 1999. Cancer Res. 59, 2566.

          Brochure

          Title
          Alzheimer's Disease Brochure & Technical Guide
          DNA Repair Pathway Poster
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision30-December-2009 RFH
          Synonyms9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one, NSC-664704
          DescriptionA potent cell-permeable and reversible inhibitor of glycogen synthase kinase-3β (IC50 = 230 nM), Lck (IC50 = 470 nM), and cyclin-dependent kinases (Cdks). Inhibits Cdk1/cyclin B (IC50 = 400 nM), Cdk2/cyclin A (IC50 = 680 nM), Cdk2/cyclin E (IC50 = 7.5 µM), and Cdk5/p25 (IC50 = 850 nM). Also inhibits other kinases such as c-Src (IC50 = 15 µM), casein kinase II (IC50 = 20 µM), ERK1 (IC50 = 20 µM), and ERK2 (IC50 = 9 µM). Inhibition is competitive with respect to ATP binding.
          FormYellow-brown solid
          Intert gas (Yes/No) Packaged under inert gas
          CAS number142273-20-9
          Chemical formulaC₁₆H₁₁BrN₂O
          Structure formulaStructure formula
          Purity≥95% by HPLC
          SolubilityDMSO (100 mg/ml)
          Storage -20°C
          Protect from light
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
          Toxicity Standard Handling
          ReferencesBain, J., et al. 2003. Biochem. J. 371, 199.
          Buolamwini, J.K. 2000. Curr. Pharm. Des. 6, 379.
          Schultz, C., et al. 1999. J. Med. Chem. 42, 2909.
          Zaharevitz, D.W., et al. 1999. Cancer Res. 59, 2566.